Clinical Trial Search

Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants

Primary: Ocular Treatment Emergent Adverse Events — 3; 3; 1; 1 Events

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus — 13.4; 13.9; 14.2; 10.8 titer

Primary: Response Rate (Partial and Complete Response) in Patients With or Without ASS Expression Present in Tumor. — 0; 4 participants

Primary: Percentage of Participants With Virologic Response at Week 12 — 92.5; 88.1; 92.5; 87.2 Percentage of participants

Primary: Definite Stent Thrombosis — 1; 0 participants

Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds

Primary: Percentage of Patients With a 2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET) Response at Day 56 in All Patients and in Epidermal Growth Factor…

Primary: Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery. — 0 Days — p=<0.025

Primary: Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period — -1.98; -0.89 Scores on a scale — p=<0.001

Primary: Percentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis) — 4.6; 2.7; 3.7; 2.1 Percentage of participants

Primary: Snore Index — 348.4; 186.2 snores per hour of monitoring — p=0.02

Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 13.0; 12.3; 12.9; 14.9 titers

Primary: Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine) — 2128; 1948 ng/mL